Analyzing Qiagen (QGEN) & Cellular Dynamics International (ICEL)

Qiagen (NASDAQ: QGEN) and Cellular Dynamics International (NASDAQ:ICEL) are both biotechnology & medical research – nec companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Valuation & Earnings

This table compares Qiagen and Cellular Dynamics International’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Qiagen $1.34 billion 5.58 $80.40 million $0.39 83.94
Cellular Dynamics International N/A N/A N/A ($1.94) -8.53

Qiagen has higher revenue and earnings than Cellular Dynamics International. Cellular Dynamics International is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

61.4% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Qiagen and Cellular Dynamics International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Qiagen 6.40% 11.36% 6.37%
Cellular Dynamics International -88.12% -57.59% -38.09%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Qiagen and Cellular Dynamics International, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen 0 7 5 0 2.42
Cellular Dynamics International 0 0 0 0 N/A

Qiagen currently has a consensus target price of $34.00, indicating a potential upside of 3.86%. Given Qiagen’s higher possible upside, equities analysts clearly believe Qiagen is more favorable than Cellular Dynamics International.

Summary

Qiagen beats Cellular Dynamics International on 10 of the 10 factors compared between the two stocks.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company’s automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Cellular Dynamics International Company Profile

Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply